Pay in 4 interest-free payments of $6.10 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Today, we announced new data from the latest Phase 3 study of retatrutide, an investigational triple hormone receptor agonist being studied for adults living with obesity or overweight with at least one weight-related comorbidity
Benefits may include: Continued appetite control Ongoing fat loss Better consistency with nutrition habits Improvements in weight-related health markers Months 6-12 Long-term treatment may continue supporting weight management goals
Wegovy (semaglutide 2.4 mg): Another GLP-1 receptor agonist, administered as a once-weekly injection
The difference often comes down to medical guidance and dosing strategy
References Jurek JM
.png?ver=V_XikP92lILtNXWLnvc1tA%3D%3D&tx=w_842)
US$ 21.98
US$ 24.58
US$ 29.76
US$ 24.87
US$ 29.77
US$ 28.20
US$ 28.43
US$ 20.29
